Press Release | NeoGenomics Laboratories

December 17, 2012

NeoGenomics Validates and Launches NeoSITE™ Barrett's Esophagus FISH Test for Surveillance and Diagnosis of High Grade Dysplasia/Esophageal Cancer

NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients